Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$254K Buy
8,919
+4,974
+126% +$132K 0.19% 88
2026
Q2
$95K Sell
3,945
-677
-15% -$17.7K 0.07% 167
2026
Q1
$130K Buy
4,622
+37
+0.8% +$985 0.11% 135
2025
Q4
$114K Buy
+4,585
New +$116K 0.1% 151

Other funds holding PFE

Bayban's PFE Position: Q3 2026 in Review

Bayban increased its Pfizer (PFE) stake by 126% in Q3 2026, buying an estimated $132K and bringing the position to 8,919 shares worth $254K. The position accounts for 0.19% of the portfolio, ranked #88.

Bayban first reported a position in PFE in Q4 2025 and has held it in 4 quarters since. 2,915 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Bayban held 8,919 shares of Pfizer worth $254K as of Q3 2026.
  • Bayban bought 4,974 Pfizer shares in Q3 2026, an estimated $132K.
  • Pfizer made up 0.19% of Bayban's portfolio in Q3 2026, its #88 holding.
  • Bayban first reported a position in Pfizer in Q4 2025 and has held it in 4 quarters since.
  • 2,915 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Bayban's 13F filing for Q3 2026, filed 5 Nov 2026.